Endovia Health Sciences Inc AI Stock Analysis
Want to see EDVA full AI Analyst Report?
Endovia Health Sciences Inc (EDVA) AI Stock Analysis
Endovia Health Sciences Inc
(NYSE MKT:EDVA)
EDVA scores near the bottom of the range, driven overwhelmingly by a distressed financial profile: essentially no revenue, negative gross profit, persistent multi-million-dollar losses, negative shareholders' equity of about -$15.7M, and years of continuous cash burn with minimal assets, creating extreme going-concern and dilution risk. Technicals reinforce the caution, with the stock far below its 100- and 200-day moving averages after a steep decline and a negative MACD. Valuation provides no support given negative earnings and no dividend. Partially offsetting these risks, recent corporate developments — FDA regulatory milestones for the CannEpil veterinary program and new incentive-aligned interim leadership — offer a potential strategic pivot, but the repeated micro-sized equity and convertible financings underscore how dependent the company remains on dilutive external capital.
Endovia Health Sciences Inc (EDVA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.59M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.48
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Endovia Health Sciences Inc Business Overview & Revenue Model
Company Description
Endovia Health Sciences is a diversified cannabinoid-based health sciences platform. The company's strategy focuses on three main areas: commercializing differentiated cannabinoid-based pharmaceutical products internationally, advancing cannabinoid-b...
Endovia Health Sciences Inc Financial Statement Overview
Summary
The financial profile is severely distressed across all three statements. Revenue has effectively evaporated — from roughly $18.9M in 2023 to $4.2M in 2024, $73K in 2025, and a negative TTM figure (-$361K) — while gross profit has turned negative, meaning there is no functioning commercial operation. Net losses remain large ($23.8M in 2024, $25.2M in 2025, $17.3M TTM) and the cost base has not scaled down with the shrinking top line. The balance sheet is technically insolvent, with shareholders' equity of about -$15.7M, roughly $6.4M of debt against only $1.1M of total assets. Operating cash flow has been negative for five-plus consecutive years (-$4.7M TTM), leaving the company entirely dependent on external financing. The only mitigating factors — reduced debt and a smaller absolute cash burn — stem from business contraction rather than genuine improvement, leaving going-concern and dilution risk extreme.
Income Statement
3Very NegativeBalance Sheet
4Very NegativeCash Flow
5Very NegativeEndovia Health Sciences Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDVA, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.19, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 51.98 is Neutral, neither overbought nor oversold. The STOCH value of 27.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EDVA.
Endovia Health Sciences Inc Risk Analysis
Endovia Health Sciences Inc disclosed 42 risk factors in its most recent earnings report. Endovia Health Sciences Inc reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksEndovia Health Sciences Inc Peers Comparison
Overall Rating
SAM64Neutral
CCU61Neutral
TAP56Neutral- EDVA42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SAM | 64Neutral | $2.23B | -32.48 | -9.81% | ― | -3.71% | -180.44% |
| CCU | 61Neutral | $2.00B | 18.95 | 7.00% | 2.66% | 5.55% | -19.14% |
| TAP | 56Neutral | $7.35B | 8.65 | 8.78% | 4.68% | -1.58% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| EDVA | 42Neutral | $1.84M | -0.02 | 170.79% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EDVA | Endovia Health Sciences, Inc. | 0.18 | -3.94 | -95.56% | |
| SAM | Boston Beer Company | 221.82 | 27.91 | 14.39% | |
| CCU | Compania Cervecerias Unidas | 10.75 | -2.18 | -16.88% | |
| TAP | Molson Coors Beverage | 40.84 | -2.81 | -6.44% | |
| YHC | Lqr House Inc. | 1.70 | -79.88 | -97.92% | |
| IBG | Innovation Beverage Group Ltd. | 0.78 | -8.22 | -91.31% |
Endovia Health Sciences Inc Corporate Events
Endovia expands equity line, boosting financing capacity
NeutralOn October 22, 2026, Endovia Health Sciences entered into an addendum to its existing Securities Purchase Agreement with C/M Capital Master Fund, LP, expanding the equity line of credit facility’s maximum commitment from $35 million to $135 million,...
Endovia Health Sciences amends equity financing agreement
PositiveOn October 15, 2026, Endovia Health Sciences amended its September 19, 2025 Securities Purchase Agreement with C/M Capital Master Fund, LP, increasing the investor’s beneficial ownership limitation from 4.99% to 9.99%, effective immediately. The part...
Endovia Health Raises Capital Through Recent Equity Issuance
PositiveOn September 30, 2026, Endovia Health Sciences, Inc. issued 526,582 shares of common stock to C/M Capital Master Fund, LP under a previously disclosed securities purchase agreement dated September 19, 2025, raising gross proceeds of $81,830.84. The t...
Endovia Gains MUMS Status for CannEpil Canine Therapy
PositiveOn October 5, 2026, Endovia Health Sciences, in partnership with Lupvindol BioSciences, reported that the FDA’s Center for Veterinary Medicine has determined CannEpil, a proprietary oral CBD and THC solution for pain associated with bone cancer in do...
Endovia Secures New Funding to Advance CannEpil Program
NeutralOn September 18, 2026, Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund, LP, under which the investor committed to provide at least $1 million to support development and commercialization of CannEpil®. The company...
Endovia secures $500,000 convertible financing for CannEpil
PositiveEndovia Health Sciences, Inc., a NYSE American‑listed cannabinoid health sciences company, has closed an initial $500,000 tranche of secured convertible debt financing from C/M Capital Master Fund, LP as of September 22, 2026. This represents the fir...
Endovia advances CannEpil amid supportive federal rescheduling move
PositiveOn August 31, 2026, Endovia Health Sciences, Inc. welcomed the federal government’s support during recent DEA administrative hearings for moving marijuana from Schedule I to Schedule III, calling it a historic shift toward a clearer regulatory framew...
Endovia Health Sciences Raises Capital Through Equity Offering
PositiveOn August 25, 2026, Endovia Health Sciences, Inc. raised $107,610.62 in gross proceeds through the sale and issuance of 510,951 shares of common stock to C/M Capital Master Fund, LP under a previously disclosed Securities Purchase Agreement dated Sep...
Endovia appoints interim leaders with incentive-focused pay
PositiveOn August 20, 2026, Endovia Health Sciences, Inc. appointed Brady Cobb as interim chief executive officer and Michael Bondurant as interim chief operating officer under new employment agreements that set base salaries of $300,000 and $275,000, respec...
Endovia launches FDA-backed CannEpil veterinary pain program
PositiveOn August 25, 2026, Endovia Health Sciences announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has opened Investigational New Animal Drug File No. 14145 for the company’s CannEpil® veterinary program. This first FDA...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026